Adam Schayowitz is an Operating Partner at EcoR1. With nearly 20 years of oncology drug development experience, Adam has led global development programs from initiation through approval and commercialization in both big pharma and biotech organizations. Prior to joining EcoR1, Adam was a Vice President at Pfizer Oncology with various development leadership roles across breast cancer, prostate cancer, colorectal cancer and melanoma. Prior to Pfizer, Adam led the development of niraparib at Tesaro and supported the commercialization of Radium-223 at Algeta. Adam currently serves on the Board of Scorpion and is an a Board Observer for Aktis Oncology.